Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Clinical trial NCT03289039 · TERMINATED
Trial details
- NCT number
- NCT03289039
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-25
- Primary completion
- 2021-07-20
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.